Introduction
============

Chronic cough is a frequent problem in general practice and one of the commonest reasons for referral to respiratory clinic. A patient\'s quality of life becomes severely affected through loss of sleep, interruption of work and social embarrassment. Every effort should be made to clarify the cause of cough because specific therapy has a higher likelihood of success than empirical therapy. A previous study revealed that patients with persistent cough had three times the risk of developing chronic wheezing as compared to normal subjects \[[@B2]\]. Thus, it is important to disclose the mechanism of persistent cough and to develop more efficacious treatment. Though cough has been considered to result from stimulation of airway sensory nerve endings within the respiratory tract \[[@B1]\], the potential mechanism by which the cough reflex may be altered in humans remains obscure.

Recently, considerable attention has been focused on the potential use of selective inhibitors of cyclic nucleotide phosphodiesterases (PDEs) in the treatment of respiratory diseases as PDE isoenzymes may play an important role in the regulation of airway caliber and bronchial smooth muscle function \[[@B3]\]. It has been shown that PDE 3 and PDE 4 are the major adenosine 3\' 5\'-cyclic monophosphate (cyclic-AMP) -- hydrolyzing enzymes and that human airway smooth muscle contains isozymes of the PDE families \[[@B4],[@B5]\]. Furthermore, human lung tissue contains multiple PDE isozymes \[[@B6]\]. Therefore, it is important to determine the possible role of inhibition of these PDE isozymes *in vivo*. Though previous research failed to prove a bronchodilator effect of a PDE 3 and PDE 4 dual inhibitor, zardaverine, in patients with partially reversible chronic airway obstruction \[[@B7]\], others indicated the protective effect of selective PDE 3 and PDE 4 inhibitors \[[@B8],[@B9]\]. We have demonstrated that a phosphodiesterase 3 inhibitor, cilostazol, reduces bronchial hyperresponsiveness to inhaled methacholine in elderly patients with stable asthma \[[@B10]\].

Based on these findings, this study was designed to elucidate the potential importance of orally administered cilostazol on cough reflex sensitivity to inhaled capsaicin in asthmatic elderly patients.

Subjects and Methods
====================

Subjects
--------

Eleven patients over 70 years with stable bronchial asthma (4 males and 7 females) with a mean age of 74.9 ± 1.3 (± SEM) (range 70--81) yrs participated in this study. All patients were lifetime nonsmokers or ex-smokers with no history of viral infection for at least 4 weeks prior to the study. Informed consent was obtained from all subjects. Characteristics of individual patients are shown in table [1](#T1){ref-type="table"}. This study was approved by the Ethics Committee of our hospital.

Each asthmatic patient satisfied the American Thoracic Society definition of asthma, with symptoms of episodic wheezing, cough, shortness of breath responding to bronchodilators and reversible airflow obstruction documented on at least one previous pulmonary function study \[[@B11]\]. Reversibility was defined as greater than 12% increase in the forced expiratory volume in one second (FEV~1~) following inhalation of 200 μg salbutamol sulfate. All patients had bronchial hyperresponsiveness as shown in table [1](#T1){ref-type="table"} and were taking oral (short-acting clenbuterol) and/or aerosol β~2~-agonists (short-acting procaterol), inhaled steroids (beclomethasone dipropionate) and/or mucolytic agents (carbocysteine). They had not received oral theophylline or oral steroid therapy for at least eight weeks. This study was carried out when their symptoms were mild and stable.

###### 

Clinical characteristics of asthmatic patients

                                                                              Treatment            
  ---- ---- --- ----- ----- ---------- ----- ------------- ---- ------ ------ ----------- --- ---- ------
  1    81   M   154   Int   Moderate   75    \-            \-   2.50   34.0   800         0   40   1500
  2    72   F   151   Ext   Moderate   464   HD            AR   2.50   25.4   800         0   0    0
  3    80   F   143   Ext   Moderate   3     Mite, HD      \-   1.25   27.0   800         0   40   0
  4    72   F   148   Int   Mild       28    \-            \-   0.08   19.4   0           0   0    1000
  5    79   F   142   Int   Moderate   37    \-            \-   5.00   27.6   800         0   20   1500
  6    72   F   150   Int   Moderate   57    \-            \-   0.31   22.3   400         0   40   0
  7    72   F   147   Ext   Moderate   647   HD, Ceder     \-   0.31   31.8   800         0   20   1500
  8    70   F   140   Int   Moderate   17    \-            \-   1.25   17.6   800         0   40   1500
  9    75   M   162   Ext   Moderate   148   HD, Ceder     AR   2.50   14.1   800         0   40   1500
  10   71   M   165   Ext   Moderate   133   Mite, Ceder   AR   1.25   14.6   0           0   40   1500
  11   80   M   165   Int   Moderate   2     \-            \-   2.50   12.6   400         0   0    0

Ext, extrinsic; Int, intrinsic; HD, house dust; AR, allergic rhinitis; BDP, beclomethasone diproprionate inhalation.

\*PC20-FEV1 shows concentration of inhaled methacholine causing a 20% fall in FEV1.

\*\*Bronchodilator response means percent increase in forced expiratory volume in 1s (FEV1) from the baseline value after inhalation of 300 μg of salbutamol sulfate.

All patients used inhaled β2-agonists (salbutamol or procaterol) on demand.

Assessment of cough reflex sensitivity to inhaled capsaicin
-----------------------------------------------------------

Cough reflex sensitivity was assessed by a capsaicin provocation test \[[@B12]\]. Capsaicin (30.5 mg) was dissolved in Tween 80 (1 mL) and ethanol (1 mL) and then dissolved in physiological saline (8 mL) to make a stock solution of 1 × 10^-2^M, which was stored at -20°C. This solution was diluted with physiological saline to make solutions starting at a concentration of 0.49 μM and increased by doubling concentrations up to 1000 μM. Each subject inhaled a control solution of physiological saline followed by progressively increasing concentrations of the capsaicin solution. Solutions were inhaled by the subjects for 15 s every 60 s, by tidal mouth-breathing whilst wearing a noseclip from a Bennett Twin nebulizer (3012-60 cc, Puritan-Bennett Co., Carlsbad, California, USA). Increasing concentrations were inhaled until five or more coughs were elicited. The nebulizer output was 0.21 mL/min. The number of capsaicin-induced coughs were counted by a blindfolded medical technician in our pulmonary function laboratory. The cough threshold was defined as the lowest concentration of capsaicin that elicited five or more coughs.

Study protocol
--------------

The subjects\' concomitant medication was stopped at 9.00 p.m. on the previous day to allow a washout time of 12 h or more before the measurement of cough threshold to inhaled capsaicin at 10.00 a.m. on each test day to reduce the diurnal variability of cough response.

Each patient attended 4 times, once every 2 weeks, at the same time each day. A control measurement of capsaicin cough threshold was carried out before the first treatment. After a two week wash out period, treatment with cilostazol and a placebo was performed in a randomized, cross-over fashion, with a washout period of 2 weeks between treatments. Two cilostazol tablets (100 mg) or their placebo were taken orally two times a day for 14 days at 8.00 a.m. on the test day. FEV~1~was measured on a dry wedge spirometer (Transfer Test, P.K. Morgan Ltd., UK) before the capsaicin challenge to assess the bronchoactive effect of the treatment regimens.

Data analysis
-------------

Capsaicin cough threshold values were expressed as a geometric mean with a geometric standard error of the mean (GSEM). Forced vital capacity (FVC) and FEV~1~were shown as arithmetic mean values ± SEM. The cough threshold, the FVC and the FEV~1~values were compared between each pair of the four test periods (run-in, placebo treatment, wash out and cilostazol treatment) by the Wilcoxon signed-ranks test. Data was transformed to logarithmic values for cough threshold at this test. A p-value of 0.05 or less was taken as significant.

Results
=======

Cough threshold to inhaled capsaicin before each treatment (run-in and washout period) and after treatment with cilostazol and placebo are shown in figure [1](#F1){ref-type="fig"}. Geometric mean values for the cough threshold were 25.9 (GSEM 1.4) μM in run-in period, 27.5 (GSEM 1.4) μM in washout period, 48.8 (GSEM 1.4) μM after cilostazol treatment and 29.2 (GSEM 1.3) μM after placebo treatment. The cough threshold after the cilostazol treatment was significantly (p \< 0.05) greater than the value after the placebo treatment. FVC or FEV1 value was not significantly different between run-in period, washout period, cilostazol treatment and placebo treatment as shown in table [2](#T2){ref-type="table"}.

![Individual data of capsaicin cough threshold before each treatment and after placebo and cilostazol treatments in elderly patients with stable bronchial asthma. Each horizontal bar represents geometric mean value. Closed circles and open circles represent patients undergoing steroid inhalation therapy and patients without steroid inhalation therapy, respectively. P values: Wilcoxon signed-ranks test using logarithmically transformed values.](1745-9974-1-11-1){#F1}

There were no changes in serum IgE and peripheral blood eosinophils, therefore, treatment with cilostazol did not affect the IgE production or peripheral blood eosinophil count. After the administration of cilostazol, none of the patients complained of headache. Other adverse effects such as palpitations, flushing and dizziness were not observed with the cilostazol treatment in patients participating in this study, since the side effects of cilostazol are less frequent in elderly patients as shown in our previous study \[[@B10]\].

###### 

Pulmonary function on cilostazol and placebo treatments in patients with bronchial asthma

                       Run-in        Placebo       Wash out      Cilostazol
  -------------------- ------------- ------------- ------------- -------------
  FVC as % pred. (%)   102.3 ± 5.7   104.7 ± 5.8   102.1 ± 5.1   108.4 ± 4.7
  FEV1 as% pred. (%)   98.5 ± 8.2    100.4 ± 7.7   98.5 ± 6.6    106.3 ± 7.3

Data are shown as mean value ± standard error of the mean.

Discussion
==========

The present study showed that two-week treatment with a PDE 3 inhibitor, cilostazol, increased the cough threshold to inhaled capsaicin in elderly patients with stable asthma. No difference could be found in the baseline pulmonary function, peripheral blood eosinophil counts and IgE production between cilostazol and placebo treatments. From these findings, PDE 3 inhibition may be useful in elderly patients suffering from bronchial asthma, especially cough predominant asthma.

Although cough is a protective reflex that facilitates the expulsion of mucus from the airways, chronic cough causes major functional limitation in a great number of people who seek medical service. It is well known that cough can be the sole manifestation in some asthmatic patients \[[@B13]\], however, the precise mechanism correlating to the cough reflex in this disorder remains obscure. A recent study revealed that inflammatory mediators play major roles in the pathogenesis of bronchial asthma, however, the relationship between inflammatory mediators and airway cough reflex sensitivity also remains unclear. Previous studies showed that some inflammatory mediators can modulate the sensitivity of the cough reflex \[[@B14],[@B15]\]. We indicated that intrinsic thromboxane A2 (TxA2) is a possible modulator, augmenting both airway cough reflex sensitivity and bronchial responsiveness whilst not having a bronchoconstricting effect in stable asthmatics \[[@B14],[@B16],[@B17]\]. Other studies reported that prostaglandin F2α (PGF2α) enhances airway cough reflex sensitivity with bronchoconstricting effect \[[@B18],[@B19]\]. It has also been shown that inhaled prostaglandin E2 (PGE2), which acts as a bronchodilator, enhances cough reflex sensitivity \[[@B19],[@B20]\]. These findings indicate the variable role of inflammatory mediators in the local control of cough reflex with no relation to bronchoconstriction.

Previous studies have shown the effects of selective inhibition of PDE isozymes in inhibition of inflammatory cell function and relaxation of airway smooth muscle in asthmatic airways \[[@B3]-[@B9],[@B21]\]. Bachelet et al have shown that alveolar macrophages from asthmatic patients have increased PDE activity \[[@B22]\]. Other researchers have indicated that PDE 3 is closely coupled to the regulation of prostaglandin D2 (PGD2) generation \[[@B23]\]. Recently we demonstrated the bronchoprotective effect of PDE 3 inhibition in asthmatic patients \[[@B10],[@B24],[@B25]\], on the basis that PDE 3 is indeed present in human airway smooth muscle \[[@B26]\]. We, therefore, carried out this study on the assumption that PDE 3 activity in an asthmatic airway might also lead to increased sensitivity of airway cough response and concluded that a selective PDE 3 inhibitor, cilostazol, can modulate to reduce the airway cough sensitivity to inhaled capsaicin. We also showed that there was no improvement in lung function despite our previous study \[[@B10]\]. Though the precise mechanism for this discordant remains obscure, we stipulate that the difference in the cilostazol administration period may be a possible cause of the discordant, because in our previous study, bronchodilation was observed with a single administration of cilostazol. Precise mechanisms for the improvement of cough reflex sensitivity indicated in this study also remains unclear because we did not measure PC20. One of the possible mechanisms is that elevation of cyclic-AMP induced by PDE 3 inhibition may play some role in the regulation of cell activity and airway cough reflex sensitivity \[[@B26]\].

Furthermore, the bronchoprotective effect of PDE 3 inhibition for non-asthmatic subjects was not examined. There is therefore a need for further studies in patients with other bronchial disorders and normal subjects.

In conclusion, the present study clearly indicates that PDE 3 inhibition can attenuate cough reflex sensitivity in the airways of elderly asthmatic patients. Oral administration of cilostazol may be a novel therapeutic option for patients with bronchial asthma, for whom cough is an especially troublesome symptom. This is the first report demonstrating the efficacy of PDE 3 inhibition in view of cough reflex sensitivity in elderly asthmatics. Further studies are required to investigate the role of other PDE isozymes in airway cough reflex sensitivity in bronchial asthma.

Abbreviations
=============

cyclic-AMP = adenosine 3\' 5\'-cyclic monophosphate; CVA = cough variant asthma; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; GSEM = geometric standard error of the mean; PDE = phosphodiesterase; PGD2 = prostaglandin D2; PGE2 = prostaglandin E2; PGF2α = prostaglandin F2α; TNF-α = tumor necrosis factor-α; TxA2 = thromboxane A2; TxB2 = thromboxane B2.
